References
- Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci 2001;114:2375–2382.
- Rodriguez S, Huynh-Do U. The role of PTEN in tumor angiogenesis. J Oncol 2011;2012:141236.
- Tamura M, Gu J, Takino T, . Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. Cancer Res 1999;59:442–449.
- Wang S-Y, Hao H-L, Deng K, . Expression levels of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration. Leuk Lymphoma 2012;53:1162–1168.
- Chang H, Qi XY, Claudio J, . Analysis of PTEN deletions and mutations in multiple myeloma. Leuk Res 2006;30:262–265.
- Sher T, Miller KC, Deeb G, . Plasma cell leukaemia and other aggressive plasma cell malignancies. Br J Haematol 2010;150:418–427.
- Varettoni M, Corso A, Pica G, . Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21:325–330.
- Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica 2007;92:143–144.
- Ge NL, Rudikoff S. Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo. Oncogene 200024;19:4091–4095.
- Ghobrial IM, Weller E, Vij R, . Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol 2011;12:263–272.
- Hofmeister CC, Yang X, Pichiorri F, . Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 2011;29:3427–3434.
- Patriarca F, Prosdocimo S, Tomadini V, . Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005;90:278–279.
- Laura R, Cibeira MT, Uriburu C, . Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 2006;76:405–408.
- Ko BS, Chang TC, Chen CH, . Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. Life Sci 2010;86:199–206.